FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Why Goldman Sachs expects Fed to skip October rate hike
Guggenheim Reiterates Buy Rating on Climb Bio (CLYM)
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $35.00 price target on Climb Bio (NASDAQ: CLYM).The analyst commented: "At ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
